Orsi, Emanuela
Solini, Anna
Bonora, Enzo
Vitale, Martina
Garofolo, Monia
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Cavalot, Franco
Laviola, Luigi
Morano, Susanna
Pugliese, Giuseppe http://orcid.org/0000-0003-1574-0397
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Independent association of atherogenic dyslipidaemia with all‐cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
https://doi.org/10.1186/s12933-021-01224-7
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-018-1133-z
Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study
https://doi.org/10.1136/bmjdrc-2020-001481
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-022-01942-8
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1371/journal.pone.0125512
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes
https://doi.org/10.1186/s12933-022-01706-2
Funding for this research was provided by:
Fondazione Diabete Ricerca
Diabetes, Endocrinology and Metabolism Foundation
Eli Lilly and Company
Sigma-Tau Pharmaceuticals
Boehringer Ingelheim
Chiesi Farmaceutici
Takeda Pharmaceutical Company
Università degli Studi di Roma La Sapienza
Article History
Received: 16 June 2022
Accepted: 4 July 2022
First Online: 28 July 2022
Declarations
:
: EO: consultant fees from Eli Lilly and Novo Nordisk, and lecture fees from Astellas. AS: consultant fees from Axxam, Bayer, and Novo Nordisk, and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. EB: consultant fees from Abbott, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, and Novo Nordisk. MVi: lecture fees from MundiPharma and Novo Nordisk. MG: consultant fees from Eli Lilly, and lecture fees from Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk. CF: lecture fees from Abbot, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Theras Lifetech. RT: consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. MVe: lecture fees from Lifescan and Novo Nordisk. FC: consultant fees from Boehringer Ingelheim, and lecture fees from AstraZeneca. LL: consultant fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, MOVI, Novo Nordisk, Roche, Sanofi-Aventis, and Terumo, and lecture fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Menarini, Merck Sharp & Dohme, MOVI, Mundipharma, Novo Nordisk, Roche, Sanofi-Aventis, and Terumo. SM: none. GPu: consultant fees from Abbot, Bayer, and Novo Nordisk, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.
: All procedures performed in this studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the coordinating center (Sant’Andrea University Hospital, Rome, Italy) on September 25, 2006 (number 43/2006), and subsequently by the ethics committee of each participating center.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.